Table 1 Clinical characteristics of GIST samples included in this study
From: miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT
Characteristics | No. of patients (%) |
|---|---|
Age (years) | |
  ≤ 55 | 68 (59.1) |
  > 55 | 47 (40.9) |
Gender | |
 Male | 63 (54.8) |
 Female | 52 (45.2) |
Primer sites | |
 Stomach | 51 (44.3) |
 Small instine | 31 (27.0) |
 Colon | 15 (13.0) |
 EGIST | 18 (15.7) |
Tumor size (cm) | |
  ≤ 5 | 41 (35.7) |
  > 5 to ≤10 | 49 (42.6) |
  > 10 | 25 (21.7) |
Histological type | |
 Spindle phenotype | 95 (82.6) |
 Epithelioid phenotype | 11 (9.6) |
 Mixed phenotype | 9 (7.8) |
Mitotic rate (per 50 HPFs) | |
  ≤ 5 | 65 (56.5) |
 6 to 10 | 27 (23.5) |
  > 10 | 23 (20.0) |
National Institutes of Health risk group | |
 Very low risk | 9 (7.8) |
 Low risk | 34 (29.6) |
 Intermediate risk | 39 (33.9) |
 High risk | 33 (28.7) |
CD117 | |
 Postive | 80 (69.6) |
 Negative | 35 (30.4) |
Relapse | |
 Yes | 12 (10.4) |
 No | 103 (89.6) |